Celsion Signs Licensing Agreement With Japanese Yakult Honsha For Liver Cancer Agent ThermoDox
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Columbia, Md.-based biotech firm Celsion signed a licensing agreement with Japan's Yakult Honsha covering Celsion's liposomal platform drug, ThermoDox, a heat-sensitive formulation of doxorubicin to treat liver cancer
You may also be interested in...
China State FDA Grants Clinical Trial Approval For Celsion's Phase III Liver Cancer Trials
SHANGHAI - China's State FDA granted clinical trial approval to Columbia, Md.-based Celsion to conduct Phase III trials in China as part of the company's global trial program for leading product ThermoDo.
China State FDA Grants Clinical Trial Approval For Celsion's Phase III Liver Cancer Trials
SHANGHAI - China's State FDA granted clinical trial approval to Columbia, Md.-based Celsion to conduct Phase III trials in China as part of the company's global trial program for leading product ThermoDo.
Celsion Initiates First International Licensing Deal With Japan’s Yakult For Liver Cancer Drug ThermoDox
TOKYO -Yakult Honsha Co. of Tokyo and Celsion of Columbia, Md., announced a licensing agreement for Celsion's liver cancer drug ThermoDox, marking Celsion's first international licensing deal